Kuros Biosciences AG Stock price

Equities

KURN

CH0325814116

Biotechnology & Medical Research

Market Closed - Swiss Exchange 12:30:28 2024-03-28 pm EDT 5-day change 1st Jan Change
6.06 CHF +3.06% Intraday chart for Kuros Biosciences AG +21.20% +73.64%
Sales 2022 17.99M 19.93M Sales 2023 33.56M 37.2M Capitalization 128M 142M
Net income 2022 -14M -15.52M Net income 2023 -13M -14.41M EV / Sales 2022 1.76 x
Net cash position 2022 22.08M 24.48M Net cash position 2023 12M 13.3M EV / Sales 2023 3.46 x
P/E ratio 2022
-3.41 x
P/E ratio 2023
-9.18 x
Employees 80
Yield 2022 *
-
Yield 2023
-
Free-Float 64.69%
More Fundamentals * Assessed data
Dynamic Chart
Kuros Biosciences' FY23 Attributable Loss Shrinks; Revenue Up MT
Kuros Biosciences AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI
US FDA Approves Kuros Biosciences' Bone Graft Granules for Interbody Use MT
Kuros Biosciences Receives US FDA 510K Clearance for Magnetos Granules for Interbody Use and Regulatory Clearance of Magnetos Granules and Magnetos Putty in New Zealand CI
Kuros Biosciences Announces Three Advancements Related to its MagnetOs Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA CI
Kuros Biosciences Announces Results from Two Prospective Randomized Clinical Trials: STRUCTURE and MAXA CI
US FDA Approves Kuros Biosciences' Fibrillar Collagen Matrix Bone Graft Substitute for Interbody Applications MT
Kuros Biosciences Receives FDA Clearance for Use of Magnetos in Interbody Spinal Cages CI
Kuros Biosciences Appoints CEO Amid Executive Management Shake-up MT
Kuros Biosciences Reports Jump in Nine-month Medical Devices Sales MT
Kuros Biosciences Books Greater Loss; Revenue Grows MT
Kuros Biosciences AG Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Kuros Biosciences Completes Patient Enrollment for Degenerative Disc Disease Drug Trial MT
Kuros Biosciences Interim CFO Named to Role Permanently MT
Kuros Biosciences' Medical Devices Sales Grow in Q1 MT
More news
1 day+3.06%
1 week+21.20%
Current month+14.34%
1 month+16.54%
3 months+74.14%
6 months+200.00%
Current year+73.64%
More quotes
1 week
5.12
Extreme 5.12
6.16
1 month
4.61
Extreme 4.61
6.16
Current year
3.50
Extreme 3.5
6.28
1 year
1.11
Extreme 1.11
6.30
3 years
1.11
Extreme 1.11
6.30
5 years
1.11
Extreme 1.11
6.30
10 years
1.11
Extreme 1.11
38.00
More quotes
Managers TitleAgeSince
Founder 58 17-12-03
Chief Executive Officer 54 21-04-18
Director of Finance/CFO - 23-02-16
Members of the board TitleAgeSince
Director/Board Member 62 18-06-13
Chief Executive Officer 54 21-04-18
Founder 58 17-12-03
More insiders
Date Price Change Volume
24-03-28 6.06 +3.06% 287,893
24-03-27 5.88 -0.68% 314,624
24-03-26 5.92 +5.71% 303,919
24-03-25 5.6 +8.95% 304,235
24-03-22 5.14 +2.80% 120,245

Delayed Quote Swiss Exchange, March 28, 2024 at 12:30 pm EDT

More quotes
Kuros Biosciences AG is a Switzerland-based biotechnology company engaged in the discovery, development and commercialization of biopharmaceutical products known as Immunodrugs. Immunodrugs are therapeutic vaccines intended for treating and preventing common chronic diseases, such as hypertension, nicotine addiction, allergic diseases, asthma, malignant melanoma and Alzheimer's disease. They are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. The Company has built a pipeline of different Immunodrug candidates, of which five are in clinical development. Its Immunodrug candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health, among others. The Company has two subsidiaries: a wholly-owned Proteome Therapeutics GmbH and minority owned BioSupport AG.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
  1. Stock
  2. Equities
  3. Stock Kuros Biosciences AG - Swiss Exchange